KaloBios short sellers facing squeeze as CEO Shkreli says will no longer lend stock
Published: Nov 27, 2015
KaloBios is reminding investors of the Volkswagen short squeeze from 2008
The trader who appealed for help on GoFundMe after a short bet on KaloBios Pharmaceuticals Inc. left him with a $106,445.56 loss may soon have company. Trader Joe Campbell asked for help on GoFundMe, when his short on the stock went wrong. Campbell says he went to bed with some $37,000 in his trading account at
E-Trade on Nov. 18 and woke up to a debt of $106,445.56.Now other shorts will scramble to cover their positions, leaving Shkreli and others who are long the stock with all the pricing power. As the remaining 20% of the company was owned by the state of Lower Saxony, which was not willing to sell, short speculators were left with no ability to cover their positions. Volkswagen stock surged to more than 1,000 euros from about 200 euros in just a few days
time to short
Look at 3 year chart.
over for CLVS.
Clovis Oncology (CLVS) has some explaining to do.
The Food and Drug Administration has requested more data on Clovis’ lead drug candidate rociletinib as it reviews the company’s new drug application, which will likely delay the drug’s approval, currently slated for March 30 of next year. More importantly, the updated results requested by FDA and released on Mondaymorning call into question rociletinib’s commercial potential, as the FDA just last week approved a similar, competing drug from AstraZeneca, with what now appears to be a superior efficacy profile.
Experimental therapy clears baby of ‘incurable’ leukemia
Shares of biotech company Cellectis pop after cancer cure
Published: Nov 6, 2015 6:57 a.m. ET
will kill ER
Conatus Pharmaceuticals Could Become A Buyout Target
By: Bret Jensen
Conatus Pharmaceuticals (NASDAQ:CNAT), a company whose main drug candidate, Emricasan, is aimed at treating a variety of liver diseases and seems a perfect fit for Gilead. Emricasan is a first-in-class, orally-active protease inhibitor designed to reduce inflammation in the liver by interfering with certain biochemical pathways. I think Gilead or any other potential acquirer will wait for positive results for Emricasan. However, given the company's "shots on goal", low market capitalization and cash on the balance sheet, I like its risk/reward profile.
Drones will be used in government, space, aviation, will be huge.
Apple shares slump as new products fail to surprise
Aaron Pressman Yahoo Finance By Aaron Pressman1 hour ago
Apple does phones an iPads ,NFLX has the streaming market. This will only make NFLX stronger as usual.